(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Exemplary Fragrances: A Manual for Notorious Scents - 2Cyber Monday 2025 streaming deal: Get $42 off six months of Apple TV
- 3Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
- 4Exploring Programming Greatness: A Survey of \Easy to use Connection points\
- 5A hospital discharged a woman in labor. This lawmaker wants change.
- The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- 2 ways you can conserve the water used to make your food
- Accomplishing Balance between fun and serious activities: Procedures for a Better Life
- 'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
- Germany and trade unions kick off tough public-sector wage talks
- The Best Internet based Courses for Expertise Improvement
- The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs
- Vote in favor of the wide open action that revives your brain and soul!
- Most loved Road Food: Which One Prevails upon You?
